Aeterna Zentaris to Present Proof of Concept for Disorazol Z Cytotoxic Conjugates such as AEZS-125 in Ovarian Cancer Mouse Model at Upcoming ENA Symposium

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, Nov. 1, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that its Director of\n Preclinical Development, Babette Aicher, PhD, will be making a poster\n presentation on preclinical results for disorazol Z cytotoxic\n conjugates, such as AEZS-125, in ovarian cancer, at the upcoming 24th EORTC-NCI-AACR (ENA) Symposium on \"Molecular Targets and Cancer\n Therapeutics\", which will be held November 6-9, 2012 in Dublin,\n Ireland. The study is funded through a grant from the German Ministry\n of Education and Research.\n\n\n\n\n\nAbstract #330: \n\n\n\"Highly Potent Cytotoxic Conjugates of Disorazol Z Linked to a\n LHRH-Receptor Targeting Peptide, such as AEZS-125, Interfere with Cell\n Cycle Progression in Human Cancer Cell Lines and Suppress Tumor Growth\n in a LHRH Receptor Positive Ovarian Cancer Xenograft Model \", B. Aicher, T. Schuster, L. Blumenstein, P. Schmidt, H. Irschik, R.\n Jansen, R. Mueller, E. Guenther, M. Teifel.\n\n\nSession: \n\n\nMonoclonal Antibodies and Targeted Toxins/Nuclides\n\n\nPoster Board:\n\n\n080\n\n\nDate& Time:  \n\n\nThursday, November 8, 2012, from 12 noon to 2:15 pm (local time)\n\n\nVenue:  \n\n\nConvention Centre Dublin\n\n\n\n\n\nAbout Disorazol Z cytotoxic conjugate, AEZS-125 \n\n\nAEZS-125 is a disorazol Z (AEZS-137) cytotoxic conjugate linked to a\n Luteinizing Hormone-Releasing Hormone (LHRH)-receptor targeting\n peptide. Disorazol Z is a novel natural compound isolated from\n myxobacterium Soranglium cellulosum with outstanding cytotoxic\n activity. Disorazol Z is a macrocyclic polyketide which is available\n via fermentation in high yield and purity. Besides tubulin binding,\n disorazol Z has pro-apoptotic properties and arrested cancer cells in\n G2 stage of the cell cycle at subnanomolar concentrations. Disorazol Z\n is an ideal partner for the formation of cytotoxic conjugates with\n peptides and proteins to selectively target cancer cells.\n\n\nAbout Aeterna Zentaris \n\n\nAeterna Zentaris is an oncology and endocrinology drug development\n company currently investigating treatments for various unmet medical\n needs. The Company's pipeline encompasses compounds at all stages of\n development, from drug discovery through to marketed products. For more\n inform...

More updates from Cosciens Biopharma Inc.